- Location
Glioma
"-
Almost 90 Percent Are Alive 20 Years Later and That Few Die From The Tumor as Adults
Feb 14, 2014The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the ...
Tags: Health&Medicine
-
Auxilium Pharmaceuticals, a biopharmaceutical company, has obtained an approval
Dec 6, 2013The US Food and Drug Administration (FDA) has granted orphan drug status for Kinex Pharmaceuticals' dual src/pre-tubulin inhibitor 'KX02' for the treatment of gliomas, which are the most common and aggressive form of brain cancer. KX02 is ...
Tags: Orphan Drug, Medicine
-
Arch Has Received US Patent for Its Brain Tumor Cell Targeting Technology
Sep 16, 2013Arch Biopartners (Arch) has received US patent for its brain tumor cell targeting technology, which protects novel synthetic peptides that target and attach human brain tumor initiating cells (BTICs) and invasive glioma cells (IGCs). The ...
-
MHLW as a Combination Therapy and Monotherapy to Treat Aggressive Form of Brain Cancer
Jun 19, 2013The Japanese Ministry of Health, Labour and Welfare (MHLW) has cleared Roche's Avastin (bevacizumab) as a combination therapy and monotherapy to treat the aggressive form of brain cancer glioblastoma. The first new medicine that is ...
Tags: Glioblastoma Therapy, Medicine
-
Activartis Has Received European Orphan Drug Designation for a Cancer Immune Therapy
Mar 13, 2013Activartis has received European orphan drug designation for a cancer immune therapy, AV0113, for use in the treatment of glioma. AV0113, which was developed against every type of cancer, is based on a procedure where the immune system ...
Tags: orphan drug, cancer immune therapy
-
Perrigo Company Has Received a Final Approval for Registration Letter
Dec 5, 2012Perrigo Company has received a final Approval for Registration letter permitting the company to sell generic temozolomide in Australia. The letter also states that bioequivalence was met between the brand product, Temodar, and the ...
-
Tocagen Has Entered Into a Partnership Agreement with MRI Interventions and Brainlab
Nov 27, 2012Clinical stage biopharmaceutical company, Tocagen, has entered into a partnership agreement with MRI Interventions and Brainlab. Under the collaboration, Tocagen will use MRI Interventions' ClearPoint neuro intervention system at selected ...
-
As Gliomas,Results Are Interesting for Treating Skin Cancer
Sep 5, 2012Results are interesting for treating skin cancer(melanoma)and nervous system tumors,known as gliomas. "Promising results"-Pablo Botella,researcher at the Institute of Chemical Technology of Valencia. Spanish researchers have ...